Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 306 articles:
HTML format



Single Articles


    February 2026
  1. DYMOCK SCC, Oommen J, Malinge S, Cheung LC, et al
    Menin inhibitors display differential in vitro sensitivity in KMT2A-rearranged infant acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 19:1-5. doi: 10.1080/10428194.2026.2631099.
    PubMed    


  2. HUGHES EE, Baron J, Wang ES, Yu H, et al
    Mini-HyperCVD in secondary acute lymphoblastic leukemia following multiple myeloma treatment from lenalidomide: a case series.
    Leuk Lymphoma. 2026 Feb 17:1-4. doi: 10.1080/10428194.2026.2631107.
    PubMed    


  3. CLAIBORNE JP, Tsai HL, Ghiaur G, Smith BD, et al
    Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2026 Feb 15:1-14. doi: 10.1080/10428194.2026.2628206.
    PubMed     Abstract available


  4. AHMED VR, Rahman FM
    NOTCH1 and SF3B1 mutations in chronic lymphocytic leukemia with their clinical associations.
    Leuk Lymphoma. 2026 Feb 14:1-8. doi: 10.1080/10428194.2026.2626937.
    PubMed     Abstract available


  5. LI B, Chen Y, Chen S, Zheng Z, et al
    Risk prediction model and survival analysis of adult patients with intracranial hemorrhage in acute leukemia.
    Leuk Lymphoma. 2026 Feb 11:1-10. doi: 10.1080/10428194.2026.2624658.
    PubMed     Abstract available


  6. CUI D, Tao Y, Zhang Y, Luo J, et al
    Clinical characteristics and treatment outcomes of pediatric Philadelphia chromosome positive acute lymphoblastic leukemia: a comparative analysis of p190 and p210 subtypes in the TKI era.
    Leuk Lymphoma. 2026 Feb 8:1-8. doi: 10.1080/10428194.2026.2624661.
    PubMed     Abstract available


  7. TAN KW, Xu Y, Huang YH, Qiu QC, et al
    Coexistence of BCR::ABL1 with IKZF1::ETV6 fusion in an adult patient with acute B-lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2621828.
    PubMed    


  8. O'BRIEN J, Tomlinson B, Patel MJ, Van Besien K, et al
    ATRA treatment in the emergency department is associated with reduced early mortality in acute promyelocytic leukemia-a real-world multicenter retrospective cohort analysis.
    Leuk Lymphoma. 2026 Feb 3:1-9. doi: 10.1080/10428194.2026.2623196.
    PubMed     Abstract available


  9. YOSHIDA K, Mushino T, Tanaka K, Kosako H, et al
    Distribution of CD30-positive tumor cell proportions in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2622526.
    PubMed    


  10. HERSTEIN JE, Marx KR, Haddad FG, Chien KS, et al
    Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2026 Feb 2:1-3. doi: 10.1080/10428194.2026.2621831.
    PubMed    


    January 2026
  11. CHUMNUMSIRIWATH P, Kongtim P, Lipan L, Jercan CG, et al
    Efficacy of CD19 CAR T-cell therapy for patients with B-cell acute lymphoblastic leukemia relapsed after allogeneic transplantation.
    Leuk Lymphoma. 2026 Jan 22:1-4. doi: 10.1080/10428194.2026.2619496.
    PubMed    


  12. JEFFREY A, Mason G, Coyle L, Mackinlay N, et al
    The spectrum of tonsillar involvement in chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2026 Jan 19:1-9. doi: 10.1080/10428194.2026.2616323.
    PubMed     Abstract available


  13. BLOMBERY P, McKeague S, Hartog B, Nguyen T, et al
    KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia.
    Leuk Lymphoma. 2026 Jan 13:1-3. doi: 10.1080/10428194.2026.2615055.
    PubMed    


  14. PULLANUR KARUMAMPURATH A, Errington A, Norman P, Hayes L, et al
    Patterns and trends in the incidence of leukemia in children and young adults in Northern England by age, sex, socioeconomic and urban-rural status.
    Leuk Lymphoma. 2026 Jan 13:1-7. doi: 10.1080/10428194.2025.2612236.
    PubMed     Abstract available


  15. HU GH, Zuo YX, Zhang XH, Wang Y, et al
    Efficacy and safety of inotuzumab ozogamicin as the definitive therapeutic option prior to allogeneic hematopoietic stem cell transplantation for pediatric relapsed/refractory B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2026 Jan 7:1-7. doi: 10.1080/10428194.2025.2611117.
    PubMed     Abstract available


  16. GUO J, Li M, Zhang L, Zhang Q, et al
    Clinical outcomes of modified busulfan plus cyclophosphamide versus total body irradiation plus cyclophosphamide for T-cell acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2026 Jan 5:1-14. doi: 10.1080/10428194.2025.2605516.
    PubMed     Abstract available


  17. LOPEZ-SANCHEZ C, van Bruggen JAC, Kater AP
    Tumor-associated disruption of T cell receptor signaling: lessons across cancers with implications for CLL.
    Leuk Lymphoma. 2026;67:306-314.
    PubMed     Abstract available


    December 2025
  18. OKA S, Ueda-Akagi Y, Mitsuyoshi T, Ono K, et al
    Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.
    Leuk Lymphoma. 2025 Dec 25:1-6. doi: 10.1080/10428194.2025.2604566.
    PubMed     Abstract available


  19. HARADA K, Iwata S, Tomita S, Nasukawa M, et al
    Cord blood versus bone marrow/peripheral blood stem cell transplantation under reduced-intensity conditioning in high-risk acute myeloid leukemia and myelodysplastic syndromes.
    Leuk Lymphoma. 2025 Dec 25:1-13. doi: 10.1080/10428194.2025.2604565.
    PubMed     Abstract available


  20. STAFYLIDIS C, Lakiotaki E, Rougala N, Giannakopoulou N, et al
    Reclassifying T-cell lymphomas in human T-lymphotropic virus 1 carriers: a familial case of adult T-cell leukemia/lymphoma with diagnostic and pathogenetic implications.
    Leuk Lymphoma. 2025 Dec 25:1-5. doi: 10.1080/10428194.2025.2606948.
    PubMed    


  21. SWAROOP A, Oh T, Wolniak K, Sukhanova M, et al
    Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.
    Leuk Lymphoma. 2025 Dec 23:1-4. doi: 10.1080/10428194.2025.2604563.
    PubMed    


  22. LIU AJ, Batterham E, Nedumannil R, Ritchie D, et al
    Reduced burden of infection with consecutive day dosing of high dose cytarabine consolidation versus conventional dosing for acute myeloid leukemia.
    Leuk Lymphoma. 2025 Dec 18:1-13. doi: 10.1080/10428194.2025.2599991.
    PubMed     Abstract available


  23. ARNAUD I, Rodriguez-Contreras FV, Aguirre-Munoz VY, Pulido M, et al
    Vincristine dose adjustments in adult acute lymphoblastic leukemia: impact on treatment outcomes and neuropathy.
    Leuk Lymphoma. 2025 Dec 17:1-10. doi: 10.1080/10428194.2025.2604567.
    PubMed     Abstract available


  24. SANCHEZ JR 2ND, Liu C, Pawar V, Huang Y, et al
    NAMPT inhibition uncovers therapeutic vulnerabilities to venetoclax and chemotherapy in acute myelogenous leukemia.
    Leuk Lymphoma. 2025 Dec 16:1-11. doi: 10.1080/10428194.2025.2571199.
    PubMed     Abstract available


  25. HAZAR V, Makiya M, Yalcin K, Cadiu JT, et al
    Prognostic factors and survival outcomes of first CNS relapse in childhood acute lymphoblastic leukemia: results from the ALL-IC REL 2016 study.
    Leuk Lymphoma. 2025 Dec 16:1-7. doi: 10.1080/10428194.2025.2598861.
    PubMed     Abstract available


  26. ZHANG LN, Pan WW, Qu H, Li Z, et al
    Quercetin induces apoptosis and autophagy in pediatric acute lymphoblastic leukemia by regulating miR-367/KLF4/JNK signaling axis.
    Leuk Lymphoma. 2025 Dec 16:1-17. doi: 10.1080/10428194.2025.2601321.
    PubMed     Abstract available


  27. LI S, Chen G, Wang H, Guan W, et al
    Pre- and post-transplant extramedullary involvement in adult patients with t(8;21)(q22;q22) acute myeloid leukemia: incidence, risk factors and outcomes.
    Leuk Lymphoma. 2025 Dec 9:1-10. doi: 10.1080/10428194.2025.2598364.
    PubMed     Abstract available


  28. KUEK V, Kotecha RS, Cheung LC
    Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.
    Leuk Lymphoma. 2025 Dec 4:1-15. doi: 10.1080/10428194.2025.2595220.
    PubMed     Abstract available


  29. PONNUSAMY U, Perumal V
    Comprehensive review on learning models of leukemia detection based on morphological information.
    Leuk Lymphoma. 2025 Dec 4:1-27. doi: 10.1080/10428194.2025.2583449.
    PubMed     Abstract available


  30. ANGELUCCI E, Deconinck E, Benoit TM, Braitsch K, et al
    Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2489-2497.
    PubMed     Abstract available


  31. HAAKSMA LH, Cloos J, Leeuw DC
    Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges.
    Leuk Lymphoma. 2025;66:2357-2368.
    PubMed     Abstract available


  32. ZHANG L, Yi M, Chen X, Guo Y, et al
    Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.
    Leuk Lymphoma. 2025;66:2457-2465.
    PubMed     Abstract available


  33. URRUTIA S, Jen WY, Sasaki K, Wiernik PH, et al
    Mortality and relapse dynamics in AML after three years of complete remission.
    Leuk Lymphoma. 2025;66:2498-2503.
    PubMed     Abstract available


  34. JERAJ R, Duan F, Mattison RJ, Romanoff J, et al
    Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).
    Leuk Lymphoma. 2025;66:2765-2773.
    PubMed     Abstract available


  35. LANE AA, Papayannidis C, Angelucci E, McCloskey J, et al
    Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2569-2577.
    PubMed     Abstract available


  36. MARTIN C, Hill K, Isoardi K
    Application of the QT nomogram to ECG monitoring of QT prolongation in arsenic trioxide for acute promyelocytic myeloid leukaemia.
    Leuk Lymphoma. 2025;66:2728-2732.
    PubMed     Abstract available


  37. SUTTON E, Shanmuganathan N, Ross D
    Clinical and biological predictors of treatment-free remission in CML.
    Leuk Lymphoma. 2025;66:2578-2587.
    PubMed     Abstract available


  38. KENNEDY VE, Touya M, Spalding J, Young C, et al
    Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.
    Leuk Lymphoma. 2025;66:2697-2707.
    PubMed     Abstract available


    November 2025
  39. GANJU N, Sharma M, Dhawan R, Oberoi G, et al
    Effect of tyrosine kinase inhibitors on sperm parameter and pituitary gonadal axis in males with chronic myeloid leukemia: a prospective cohort study.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2584688.
    PubMed     Abstract available


  40. MOHAMMED SALEH MF, Nasiri A, Kotb A, Ahmed SO, et al
    The emerging role of immunotherapy in improving outcomes in Down syndrome - associated acute lymphoblastic leukemia: an insightful review.
    Leuk Lymphoma. 2025 Nov 20:1-8. doi: 10.1080/10428194.2025.2590596.
    PubMed     Abstract available


  41. LAGANA A, Scalzulli E, Carmosino I, Bisegna ML, et al
    Early predictive factors of molecular relapse in chronic phase-chronic myeloid leukemia (CP-CML) patients after tyrosine kinase inhibitor (TKI) discontinuation.
    Leuk Lymphoma. 2025 Nov 20:1-5. doi: 10.1080/10428194.2025.2591778.
    PubMed    


  42. SUN Y, Aviv H
    Neuroendocrine transdifferentiation of aggressive B-cell leukemia/lymphoma post CAR-T therapy.
    Leuk Lymphoma. 2025 Nov 19:1-4. doi: 10.1080/10428194.2025.2589375.
    PubMed    


  43. CALVILLO CD, Cardenas Castro V, Shim KG, Arribas M, et al
    NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.
    Leuk Lymphoma. 2025 Nov 19:1-7. doi: 10.1080/10428194.2025.2586084.
    PubMed     Abstract available


  44. CHO C, Redd R, Haydu JE, Johnson PC, et al
    Central nervous system involvement in chronic lymphocytic leukemia: a real-world analysis.
    Leuk Lymphoma. 2025 Nov 18:1-5. doi: 10.1080/10428194.2025.2581717.
    PubMed    


  45. LATAGLIATA R, Carmosino I, Di Veroli A, Scalzulli E, et al
    Hemoglobin changes during long-lasting frontline treatment with Tyrosine-Kinase inhibitors in patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Nov 17:1-6. doi: 10.1080/10428194.2025.2586816.
    PubMed     Abstract available


  46. GUO X, Wang X, Wang Y, Rong L, et al
    Long-term remission of CBFA2T3::GLIS2-positive pediatric acute myeloid leukemia with myeloid sarcoma following unrelated cord blood transplantation.
    Leuk Lymphoma. 2025 Nov 13:1-4. doi: 10.1080/10428194.2025.2584684.
    PubMed    


  47. CHEVILLON F, Dhedin N, Boissel N
    Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape.
    Leuk Lymphoma. 2025 Nov 13:1-13. doi: 10.1080/10428194.2025.2584685.
    PubMed     Abstract available


  48. VALDOVINOS-ELIZALDE LE, Rios-Olais FA, Hernandez-Felix JH, Vasquez-Ortiz ZY, et al
    Prognostic value of HFA-ICOS risk assessment for cancer therapy-related cardiovascular toxicity in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Nov 11:1-9. doi: 10.1080/10428194.2025.2583445.
    PubMed     Abstract available


  49. SALTER B, Ge S, Garcia-Horton A, Berg T, et al
    Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2025 Nov 5:1-8. doi: 10.1080/10428194.2025.2577861.
    PubMed    


  50. NGO D, Kaleka G, Yang D, Mokhtari S, et al
    Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351).
    Leuk Lymphoma. 2025 Nov 5:1-4. doi: 10.1080/10428194.2025.2584682.
    PubMed    


  51. GOUZU Y, Ide Y, Shigeto S, Saito T, et al
    Chemotherapy-associated lineage shift of T/myeloid mixed-phenotype acute leukemia into AML-MRC: a case report.
    Leuk Lymphoma. 2025 Nov 5:1-5. doi: 10.1080/10428194.2025.2582716.
    PubMed    


    October 2025
  52. ICHIMURA H, Kato S, Monna-Oiwa M, Andoh S, et al
    Comparative analysis of the acute myeloid leukemia-composite model and treatment-related mortality score in single-unit cord blood transplantation.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2571201.
    PubMed    


  53. NING Y, Stinnett V, Middlezong W, Liang S, et al
    Detection of cytogenetic abnormalities using optical genome mapping in T-cell lymphoid leukemia with low mitotic index.
    Leuk Lymphoma. 2025 Oct 31:1-4. doi: 10.1080/10428194.2025.2562960.
    PubMed    


  54. AZEVEDO RS, Braish J, Gener-Ricos G, Tang G, et al
    Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2568745.
    PubMed    


  55. ZHAO Y, Chen J, Xu L, Lin D, et al
    Acute promyelocytic leukemia with TTMV::RARA fusion: a case report and mini review.
    Leuk Lymphoma. 2025 Oct 31:1-5. doi: 10.1080/10428194.2025.2571420.
    PubMed    


  56. HUNTER CJ, Cheng W, Bewersdorf JP, Boddu P, et al
    Feasibility, safety and outcomes of patients with newly diagnosed acute myeloid leukemia discharged 'early' after intensive induction.
    Leuk Lymphoma. 2025 Oct 29:1-12. doi: 10.1080/10428194.2025.2578420.
    PubMed     Abstract available


  57. BAK A, Pasinska M, Jaskowiec A, Potoczek S, et al
    Germline predisposition to acute myeloid leukemia in polish patients.
    Leuk Lymphoma. 2025 Oct 27:1-8. doi: 10.1080/10428194.2025.2571421.
    PubMed     Abstract available


  58. STANGANELLI C, Cardoso F, Cabrera J, Damiani G, et al
    IGLV3-21 subset #2 without IGLV3-21(R110) in chronic lymphocytic leukemia, is it possible?
    Leuk Lymphoma. 2025 Oct 26:1-4. doi: 10.1080/10428194.2025.2561115.
    PubMed    


  59. ARANI N, Rausch CR, Geppner A, Borthakur G, et al
    Cladribine and venetoclax combined with alemtuzumab in patients with relapsed/refractory T-cell prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Oct 22:1-5. doi: 10.1080/10428194.2025.2566318.
    PubMed    


  60. LIN J, He C, Cai Z, Chen J, et al
    Pediatric-inspired regimen abrogates the poor prognosis of adult early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Oct 16:1-8. doi: 10.1080/10428194.2025.2558921.
    PubMed     Abstract available


  61. MCCORMICK B, Findley A, Diebold K, Bourne G, et al
    Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 10:1-11. doi: 10.1080/10428194.2025.2564766.
    PubMed     Abstract available


  62. PARK H, Lee JH, Lee JH, Park HS, et al
    Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients.
    Leuk Lymphoma. 2025 Oct 10:1-14. doi: 10.1080/10428194.2025.2560086.
    PubMed     Abstract available


  63. TADMOR T, Demeter J, Fagarasanu A, Kreitman RJ, et al
    Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
    Leuk Lymphoma. 2025 Oct 10:1-7. doi: 10.1080/10428194.2025.2562961.
    PubMed     Abstract available


  64. WATRIN T, Seifert M, Dietrich S
    The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
    Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
    PubMed     Abstract available


  65. HUANG YH, Liu FT, Wan CL, Wang ZJ, et al
    Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.
    Leuk Lymphoma. 2025 Oct 6:1-11. doi: 10.1080/10428194.2025.2566317.
    PubMed     Abstract available


    September 2025
  66. WANG Y, Xiao X, Zheng H, Bai J, et al
    The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Lymphoma. 2025 Sep 9:1-16. doi: 10.1080/10428194.2025.2549519.
    PubMed     Abstract available


  67. PARISI X, Ghosh A, Tang G, Jorgensen JL, et al
    Lineage switch of B-lymphoblastic leukemia with KMT2A::AFF1 fusion into acute myelomonocytic leukemia under blinatumomab therapy.
    Leuk Lymphoma. 2025 Sep 8:1-4. doi: 10.1080/10428194.2025.2549515.
    PubMed    


  68. SINGH L, Rastogi K, Singh A, Sathapathy S, et al
    Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.
    Leuk Lymphoma. 2025 Sep 5:1-13. doi: 10.1080/10428194.2025.2550580.
    PubMed     Abstract available


  69. XU K, Mellios Z, Hyun J, Childerhouse A, et al
    Diagnosis and management of acute erythroid leukemia (AEL).
    Leuk Lymphoma. 2025 Sep 2:1-5. doi: 10.1080/10428194.2025.2553166.
    PubMed    


  70. BRAZEL D, Hermel DJ, Saven A
    Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.
    Leuk Lymphoma. 2025 Sep 1:1-8. doi: 10.1080/10428194.2025.2548373.
    PubMed     Abstract available


  71. ABBASI-SHAHKOUH A, Rashidan K, Azadmehr A, Atashi A, et al
    Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2547990.
    PubMed     Abstract available


    August 2025
  72. TESSIER S, Greipp PT, Jevremovic D, Alkhateeb HB, et al
    Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
    Leuk Lymphoma. 2025 Aug 25:1-6. doi: 10.1080/10428194.2025.2547988.
    PubMed    


  73. LIPTON JH
    Indolent chronic myeloid leukemia - a historical dinosaur?
    Leuk Lymphoma. 2025 Aug 22:1-2. doi: 10.1080/10428194.2025.2536121.
    PubMed    


  74. AMIRI D, Mirzaei M, Bahri T, Barkhordar M, et al
    Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
    Leuk Lymphoma. 2025 Aug 20:1-9. doi: 10.1080/10428194.2025.2548968.
    PubMed     Abstract available


  75. KARRAR O, Kantarjian H, Haddad FG, Azevedo RS, et al
    Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma. 2025 Aug 9:1-8. doi: 10.1080/10428194.2025.2542946.
    PubMed     Abstract available


  76. MATSUI S, Nakahara W, Fukuda S, Hosoya M, et al
    Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient.
    Leuk Lymphoma. 2025 Aug 9:1-4. doi: 10.1080/10428194.2025.2544067.
    PubMed    


  77. PARK H, Lee JH, Lee JH, Park HS, et al
    Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.
    Leuk Lymphoma. 2025 Aug 7:1-11. doi: 10.1080/10428194.2025.2541302.
    PubMed     Abstract available


  78. AGRAWAL V, Aldoss I, Pullarkat V
    Extramedullary sites of disease in B-cell acute lymphoblastic leukemia: incidence, biology, and treatment.
    Leuk Lymphoma. 2025 Aug 5:1-12. doi: 10.1080/10428194.2025.2541024.
    PubMed     Abstract available


  79. ZIELONKA K, Izdebski B, Drozd-Sokolowska J, Pruszczyk-Matusiak K, et al
    Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group.
    Leuk Lymphoma. 2025 Aug 1:1-9. doi: 10.1080/10428194.2025.2535693.
    PubMed     Abstract available


    July 2025
  80. LU L, Liang J, Wang L, Chen Z, et al
    Venetoclax promotes acute myeloid leukemia cells apoptosis by decreasing ac4C modification and mRNA expression of IMP3 through downregulating NAT10.
    Leuk Lymphoma. 2025 Jul 31:1-11. doi: 10.1080/10428194.2025.2540445.
    PubMed     Abstract available


  81. PODGORICA M, Drivet E, Vestbostad J, Kvam AK, et al
    Azaindole 1, a selective Rock1/2 kinase inhibitor, induces G2/M arrest and cell death in B-cell acute lymphoblastic leukemia (B-ALL).
    Leuk Lymphoma. 2025 Jul 29:1-5. doi: 10.1080/10428194.2025.2536125.
    PubMed    


  82. MULLIGAN SP, Thompson PA, Wight J, Anderson MA, et al
    Real-world utilization of Bruton tyrosine kinase inhibitors in relapsed/refractory chronic lymphocytic leukemia in Australia.
    Leuk Lymphoma. 2025 Jul 27:1-11. doi: 10.1080/10428194.2025.2533498.
    PubMed     Abstract available


  83. LIU YC, van Besien KW
    Chronic myelomonocytic leukemia (CMML): a genetically heterogeneous entity.
    Leuk Lymphoma. 2025 Jul 22:1-3. doi: 10.1080/10428194.2025.2527389.
    PubMed    


  84. WU Y, Ke Q, Liu B, Luo W, et al
    KLF2 double variants (C274Y and H210N) in a splenic B-cell lymphoma/leukemia: diagnostic insights into splenic marginal zone lymphoma and mechanistic implications.
    Leuk Lymphoma. 2025 Jul 15:1-5. doi: 10.1080/10428194.2025.2532680.
    PubMed    


  85. LI THS, Yuen CT, Hou HW, Lam CP, et al
    Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation.
    Leuk Lymphoma. 2025 Jul 14:1-3. doi: 10.1080/10428194.2025.2529451.
    PubMed    


  86. ASHFAQ MO, Iqbal MS, Ashfaq L, Irfan U, et al
    Challenging diagnosis of chronic myelomonocytic leukemia (CMML) in a patient with Takayasu arteritis: case report.
    Leuk Lymphoma. 2025 Jul 13:1-4. doi: 10.1080/10428194.2025.2526792.
    PubMed    


  87. KOFFMAN B, Warwick L, Haggert P, Patten PEM, et al
    A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence.
    Leuk Lymphoma. 2025 Jul 12:1-7. doi: 10.1080/10428194.2025.2521656.
    PubMed     Abstract available


  88. UYANIK MS, Jabbour E, Short N, Sasaki K, et al
    Nelarabine-related rhabdomyolysis in adult patients with T-cell lymphoblastic leukemia/lymphoma: a report of 6 patients.
    Leuk Lymphoma. 2025 Jul 6:1-3. doi: 10.1080/10428194.2025.2521649.
    PubMed    


  89. FENG J, Qian W, Shan S, Wang G, et al
    Azathioprine as a substitute for 6-mercaptopurine in childhood acute lymphoblastic leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2025 Jul 6:1-9. doi: 10.1080/10428194.2025.2526795.
    PubMed     Abstract available


  90. GULLAKSEN SE, Omsland M, Brevik M, Letzner J, et al
    CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2025;66:1211-1220.
    PubMed     Abstract available


    June 2025
  91. SLATER VE, Carnahan RM, Strouse CS, O'Rorke MA, et al
    Changes in first-line treatment patterns according to frailty in chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Jun 26:1-12. doi: 10.1080/10428194.2025.2522373.
    PubMed     Abstract available


  92. SARANGARAJAN S, Meena JP, Gupta AK, Batra A, et al
    The prognostic implications of CDKN2A/2B deletion in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2025 Jun 25:1-14. doi: 10.1080/10428194.2025.2521658.
    PubMed     Abstract available


  93. MAURO MJ, Hehlmann R, Williams LA, Goldberg SL, et al
    Five-year molecular response and overall survival with first- and second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: a prospective, observational study - SIMPLICITY.
    Leuk Lymphoma. 2025 Jun 22:1-10. doi: 10.1080/10428194.2025.2495369.
    PubMed     Abstract available


  94. SWAIN RN, Pattanaik S, Jain A, Wadhera S, et al
    Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough.
    Leuk Lymphoma. 2025 Jun 22:1-5. doi: 10.1080/10428194.2025.2519921.
    PubMed    


  95. KUNDU R, Soni K, Kundu R, Mukherjee S, et al
    State-wise disparities and temporal trends in acute myeloid leukemia (AML) in the United States of America (USA).
    Leuk Lymphoma. 2025 Jun 20:1-6. doi: 10.1080/10428194.2025.2515598.
    PubMed     Abstract available


  96. PUROHIT BN, Mohan V, Capoor V, Jain S, et al
    Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia.
    Leuk Lymphoma. 2025 Jun 18:1-4. doi: 10.1080/10428194.2025.2519920.
    PubMed    


  97. LAI CE, Leahy TP, Turner AJ, Thomassen A, et al
    Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control
    Leuk Lymphoma. 2025 Jun 13:1-12. doi: 10.1080/10428194.2025.2514894.
    PubMed     Abstract available


  98. SMITH CIE
    Resistance to BTK inhibitors in leukemia: cysteine 481 in BTK equals cysteine 515 in the BTK isomer BTK-C.
    Leuk Lymphoma. 2025 Jun 12:1-2. doi: 10.1080/10428194.2025.2518433.
    PubMed    


  99. DAMPMANN M, von Tresckow B, Reinhardt HC, Kuppers R, et al
    Insights into the pathogenesis and biology of chronic lymphocytic leukemia through analysis of its B-cell receptor.
    Leuk Lymphoma. 2025 Jun 10:1-10. doi: 10.1080/10428194.2025.2513005.
    PubMed     Abstract available


  100. KAMALLOO H, Fathi M, Bavandi S, Asadi F, et al
    Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jun 2:1-13. doi: 10.1080/10428194.2025.2507198.
    PubMed     Abstract available


  101. JANY J, Mikesch JH, Wethmar K, Baden D, et al
    Prognostic impact of WBC kinetics after induction therapy in patients with acute myeloid leukemia (AML).
    Leuk Lymphoma. 2025 Jun 2:1-12. doi: 10.1080/10428194.2025.2512029.
    PubMed     Abstract available


    May 2025
  102. LEVY V, Srivastava T, Gautam R, Swami S, et al
    Toxicity, progression-free survival, and quality of life of patients treated with zanubrutinib versus ibrutinib: a Q-TWiST analysis from the ALPINE study in relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 May 23:1-9. doi: 10.1080/10428194.2025.2506501.
    PubMed     Abstract available


  103. MEHTA P, Ngo D, Tinajero J, Agrawal V, et al
    Comparison of CALGB 10403 and HyperCVAD in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia in adults >/=40 years old.
    Leuk Lymphoma. 2025 May 21:1-5. doi: 10.1080/10428194.2025.2506003.
    PubMed    


  104. SHI C, Li Y, Zou X, Yao D, et al
    AP2M1 is a prognostic marker associated with cell cycle arrest and the tumor immune microenvironment in acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-15. doi: 10.1080/10428194.2025.2504161.
    PubMed     Abstract available


  105. HILL JW, Marvin-Peek J, Sasaki K, Bresser S, et al
    Central nervous system relapse of core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2025 May 19:1-4. doi: 10.1080/10428194.2025.2506505.
    PubMed    


  106. TADMOR T, Lavie G, Melamed G, Alapi H, et al
    Intake of benzodiazepines in treatment naive chronic lymphocytic leukemia patients is associate with a shorter time to first treatment.
    Leuk Lymphoma. 2025 May 15:1-6. doi: 10.1080/10428194.2025.2504155.
    PubMed     Abstract available


  107. OTHMAN T, Lo MM, Andreadis CB, Damon LE, et al
    Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma. 2025 May 7:1-4. doi: 10.1080/10428194.2025.2496333.
    PubMed    


  108. GORDON BK, Woyach JA
    The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.
    Leuk Lymphoma. 2025;66:838-846.
    PubMed     Abstract available


  109. MCKEAGUE S, Tam C
    Prognostic factors in chronic lymphocytic leukaemia - the old, the new and the future.
    Leuk Lymphoma. 2025;66:847-857.
    PubMed     Abstract available


  110. RAMACHANDRA N, Vegivinti CTR, Sahu S, Sanawar R, et al
    Transforming growth factor beta receptor type I (TGF-betaRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
    Leuk Lymphoma. 2025;66:920-929.
    PubMed     Abstract available


    April 2025
  111. SHALLIS RM, Weiss JJ, Winer ES, Badar T, et al
    Feasibility and safety of outpatient hypomethylating agent and venetoclax initiation with and without ramp-up for newly diagnosed acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
    Leuk Lymphoma. 2025 Apr 28:1-5. doi: 10.1080/10428194.2025.2496339.
    PubMed    


  112. LAGANA A, Kasmi D, Diverio D, Bisegna ML, et al
    CD99 expression in acute myeloid leukemia with FLT3 internal tandem duplications (FLT3-ITD(mut)-AML): a flow-cytometric marker for an accurate diagnostic workup.
    Leuk Lymphoma. 2025 Apr 28:1-6. doi: 10.1080/10428194.2025.2497392.
    PubMed     Abstract available


  113. ELHODAKY M, Duckett D, Santana-Santos L, Oh TS, et al
    Clinicopathological and global methylation profiling of acute myeloid leukemia with mutations in NPM1 and clonal hematopoiesis-related genes.
    Leuk Lymphoma. 2025 Apr 25:1-8. doi: 10.1080/10428194.2025.2495105.
    PubMed     Abstract available


  114. BEHMAN J, Longobardi S, Kang G, Lingamurthy M, et al
    CD5- B-cell lymphocytic leukemia -a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus.
    Leuk Lymphoma. 2025 Apr 22:1-4. doi: 10.1080/10428194.2025.2492608.
    PubMed    


  115. LEVANON E, Peles I, Meyer E, Tarab E, et al
    Prognostic impact of fever at presentation in acute myeloid leukemia: a retrospective cohort study.
    Leuk Lymphoma. 2025 Apr 17:1-11. doi: 10.1080/10428194.2025.2493342.
    PubMed     Abstract available


  116. PATEL M, Zabor EC, Mohamed A, Zureigat H, et al
    Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center.
    Leuk Lymphoma. 2025 Apr 9:1-6. doi: 10.1080/10428194.2025.2482131.
    PubMed     Abstract available


  117. DHAKAL P, Armitage JO, Bhatt VR
    Academic and community cancer center collaboration in acute myeloid leukemia: a road map to optimize care delivery.
    Leuk Lymphoma. 2025 Apr 1:1-11. doi: 10.1080/10428194.2025.2484640.
    PubMed     Abstract available


    March 2025
  118. KUGLER E, Dasdemir E, Bataller A, Wang B, et al
    Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.
    Leuk Lymphoma. 2025 Mar 31:1-13. doi: 10.1080/10428194.2025.2477723.
    PubMed     Abstract available


  119. JOHANSSON ALM S, Orrsjo G, Shah Barkhordar G, Rehammar A, et al
    Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.
    Leuk Lymphoma. 2025 Mar 31:1-11. doi: 10.1080/10428194.2025.2482130.
    PubMed     Abstract available


  120. FERREIRA JE, Wang CP, Aguayo-Hiraldo P, Raca G, et al
    Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy.
    Leuk Lymphoma. 2025 Mar 25:1-5. doi: 10.1080/10428194.2025.2482135.
    PubMed    


  121. ROBAK T, Pluta A, Robak P, Janus A, et al
    Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.
    Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
    PubMed     Abstract available


  122. JAIN N, Eyre TA, Winfree KB, Bhandari NR, et al
    Real-world outcomes after discontinuation of covalent BTK inhibitor-based therapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2025 Mar 23:1-13. doi: 10.1080/10428194.2025.2482132.
    PubMed     Abstract available


  123. MONSEES EL, Hauch RT, Wrzeszcz A, Spohn M, et al
    A case report of a pediatric T-cell acute lymphoblastic leukemia with a subclonal GCC2::PDGFRB t(2;5) translocation - implementation for the selection of MRD-targets.
    Leuk Lymphoma. 2025 Mar 19:1-5. doi: 10.1080/10428194.2025.2480395.
    PubMed    


  124. AMREIN PC, Preffer FI, Fell G, Attar EC, et al
    Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
    Leuk Lymphoma. 2025 Mar 12:1-11. doi: 10.1080/10428194.2025.2476655.
    PubMed     Abstract available


  125. HOECHSTETTER MA, Wendtner CM
    Clinical trials in early-stage CLL: what has been learned and what's next?
    Leuk Lymphoma. 2025;66:378-388.
    PubMed     Abstract available


  126. ALHAJAHJEH A, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML.
    Leuk Lymphoma. 2025;66:488-496.
    PubMed     Abstract available


  127. LI Q, Xing S, Zhang H, Mao X, et al
    FISH combined with RT-PCR facilitates classification of Chinese adult patients with B-other ALL through improved identification of ZNF384 rearrangement.
    Leuk Lymphoma. 2025;66:507-515.
    PubMed     Abstract available


    February 2025
  128. TAN M, Lasica M, Donati V, Rady K, et al
    Avascular necrosis in older adolescents and adults with acute lymphoblastic leukemia treated with FRALLE protocols: a multicenter analysis of incidence, risk factors and morbidity.
    Leuk Lymphoma. 2025 Feb 27:1-7. doi: 10.1080/10428194.2025.2470784.
    PubMed     Abstract available


  129. GRUESSNER C, Wiestner A, Sun C
    Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.
    Leuk Lymphoma. 2025 Feb 19:1-13. doi: 10.1080/10428194.2025.2466101.
    PubMed     Abstract available


  130. SHESTAKOVA A, Haghighi N, Zhang Y, Tarabay J, et al
    Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system.
    Leuk Lymphoma. 2025 Feb 18:1-6. doi: 10.1080/10428194.2025.2452341.
    PubMed    


  131. SUN Y, Liu N, Liu Y, Deng J, et al
    Isolated CNS B lymphoid/myeloid bilineage relapse following allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with KMT2A::MLLT1 rearrangement.
    Leuk Lymphoma. 2025 Feb 10:1-4. doi: 10.1080/10428194.2025.2460046.
    PubMed    


  132. THOMAS CJ, Porter D, Van Deerlin VM, Bhattacharyya S, et al
    Aleukemic soft-tissue relapse post allogeneic hematopoietic cell transplantation in T-prolymphocytic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-4. doi: 10.1080/10428194.2025.2462950.
    PubMed    


  133. LANG F, Voss A, Kobbe G, Junghanss C, et al
    Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Feb 8:1-9. doi: 10.1080/10428194.2025.2460737.
    PubMed     Abstract available


  134. CHIN KK, Derkach A, Famulare C, Gupta GK, et al
    HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.
    Leuk Lymphoma. 2025;66:270-278.
    PubMed     Abstract available


    January 2025
  135. KRSTEVSKA BOZHINOVIKJ E, Matevska-Geshkovska N, Staninova Stojovska M, Gjorgievska E, et al
    Presence of minimal residual disease determined by next-generation sequencing is not a reliable prognostic biomarker in children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 22:1-8. doi: 10.1080/10428194.2025.2456100.
    PubMed     Abstract available


  136. JEONG Y
    Comprehensive analysis of clinical, pathological, and molecular features in chronic myelomonocytic leukemia: frequent ASXL1 and NRAS mutations and higher mutation burden in myeloproliferative CMML compared to myelodysplastic CMML.
    Leuk Lymphoma. 2025 Jan 17:1-10. doi: 10.1080/10428194.2025.2453093.
    PubMed     Abstract available


  137. TESSIER S, McCullough KB, Gangat N, Begna KH, et al
    Venetoclax in combination with fludarabine, cytarabine, granulocyte colony stimulating factor, and idarubicin (FLAG-Ida) in patients with acute leukemia of ambiguous lineage and acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 16:1-5. doi: 10.1080/10428194.2024.2443017.
    PubMed    


  138. HEILBRONNER AK, Blumberg O, Krez A, McMahon DJ, et al
    High incidence of multi-joint osteonecrosis in first year following treatment for acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 15:1-4. doi: 10.1080/10428194.2025.2452340.
    PubMed    


  139. ZHU H, Zhang C, Huang L, Zhang B, et al
    Identification of possible drug treatment targets and related immune cell infiltration properties in acute myeloid leukemia utilizing robust rank aggregation algorithm.
    Leuk Lymphoma. 2025 Jan 15:1-12. doi: 10.1080/10428194.2025.2451064.
    PubMed     Abstract available


  140. LI M, Zhao DQ, Kong XY, Wang SM, et al
    Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2025 Jan 11:1-11. doi: 10.1080/10428194.2025.2451059.
    PubMed     Abstract available


  141. SENAPATI J, Kantarjian H, Habib D, Haddad FG, et al
    Frontline immunotherapeutic combination strategies in adult B-cell acute lymphoblastic leukemia: reducing chemotherapy intensity and toxicity and harnessing efficacy.
    Leuk Lymphoma. 2025 Jan 10:1-12. doi: 10.1080/10428194.2025.2449582.
    PubMed     Abstract available


  142. ZHANG F, Liu Y, Zhu Y, Wang Q, et al
    Molecular, clinical, and prognostic implications of RAS pathway alterations in adult acute myeloid leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-11. doi: 10.1080/10428194.2024.2441855.
    PubMed     Abstract available


  143. YSEBAERT L, Mouchel PL, Laurent C, Quillet-Mary A, et al
    The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2025 Jan 2:1-13. doi: 10.1080/10428194.2024.2447362.
    PubMed     Abstract available


    December 2024
  144. AVGERINOU G, Solomou EE, Filippidou M, Perganti F, et al
    Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Dec 28:1-4. doi: 10.1080/10428194.2024.2445701.
    PubMed    


  145. GUGLIELMANA V, Rossi D
    Prognostic and predictive impact of NOTCH1 mutation in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2441858.
    PubMed     Abstract available


  146. NILSSON MS, Martner A, Wennstrom L, Hansson M, et al
    Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Dec 24:1-3. doi: 10.1080/10428194.2024.2444466.
    PubMed    


  147. DAMPMANN M, Kibler A, von Tresckow J, Reinhardt HC, et al
    Single-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
    Leuk Lymphoma. 2024 Dec 17:1-9. doi: 10.1080/10428194.2024.2438804.
    PubMed     Abstract available


  148. OLIAI C, Park S, Damon LE, Jonas BA, et al
    CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.
    Leuk Lymphoma. 2024 Dec 17:1-7. doi: 10.1080/10428194.2024.2438809.
    PubMed     Abstract available


  149. SHELLEY CS, Galiegue-Zouitina S, Andritsos LA, Epperla N, et al
    The role of the JunD-RhoH axis in the pathogenesis of hairy cell leukemia and its ability to identify existing therapeutics that could be repurposed to treat relapsed or refractory disease.
    Leuk Lymphoma. 2024 Dec 17:1-19. doi: 10.1080/10428194.2024.2438800.
    PubMed     Abstract available


  150. ISHIKAWA C, Mori N
    ML385, a selective inhibitor of Nrf2, demonstrates efficacy in the treatment of adult T-cell leukemia.
    Leuk Lymphoma. 2024 Dec 17:1-12. doi: 10.1080/10428194.2024.2441875.
    PubMed     Abstract available


  151. KOVACH AE, Komova D, Itov A, Gaskova M, et al
    Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype.
    Leuk Lymphoma. 2024;65:1840-1852.
    PubMed     Abstract available


  152. MINA A
    Targeted therapy in acute T-cell leukemia/lymphoma: are we close?
    Leuk Lymphoma. 2024 Dec 1:1-3. doi: 10.1080/10428194.2024.2432575.
    PubMed    


  153. PAISIOU A, OIkonomopoulou C, Pavlidis D, Ampatzidou M, et al
    CDKN2A/B deletion as an independent negative prognostic factor for allogeneic hematopoietic stem cell transplantation in childhood B cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2434177.
    PubMed    


  154. RIOS-OLAIS FA, Rodriguez-Rodriguez S, Mora-Canas A, Ramos-Penafiel CO, et al
    Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Dec 1:1-4. doi: 10.1080/10428194.2024.2432582.
    PubMed    


  155. EHRMANN AS, Zadro A, Tausch E, Schneider C, et al
    The NOTCH1 and miR-34a signaling network is affected by TP53 alterations in CLL.
    Leuk Lymphoma. 2024;65:1941-1953.
    PubMed     Abstract available


  156. ARAD-COHEN N, Messinger Y, Barzilai-Birenboim S, Ben-Harosh M, et al
    National study reveals gram negative bacteremia on contemporary pediatric AML protocol.
    Leuk Lymphoma. 2024;65:1991-1999.
    PubMed     Abstract available


  157. TASHAKORI M, Yohe S, Linden MA, McKenna RW, et al
    The prognostic effect of blast count in TP53 mutant myeloid neoplasms -the Minnesota experience.
    Leuk Lymphoma. 2024;65:2151-2162.
    PubMed     Abstract available


  158. BOHN JP, Stolzlechner V, Gobel G, Pirklbauer M, et al
    Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function.
    Leuk Lymphoma. 2024;65:2108-2115.
    PubMed     Abstract available


    November 2024
  159. PAUL S, Jabbour E, Nichols ED, Short NJ, et al
    Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
    Leuk Lymphoma. 2024 Nov 29:1-11. doi: 10.1080/10428194.2024.2426052.
    PubMed     Abstract available


  160. SHORT NJ, Wierzbowska A, Cluzeau T, Laribi K, et al
    Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-11. doi: 10.1080/10428194.2024.2431878.
    PubMed     Abstract available


  161. MIMS A, Xie Z, Potluri R, Rotter D, et al
    Oral azacitidine maintenance after intensive chemotherapy versus venetoclax and azacitidine: real world outcomes in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 28:1-9. doi: 10.1080/10428194.2024.2425792.
    PubMed     Abstract available


  162. COSTA A, Scalzulli E, Carmosino I, Ielo C, et al
    Clinical and biological advances of critical complications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 24:1-20. doi: 10.1080/10428194.2024.2425051.
    PubMed     Abstract available


  163. ARRIGO G, Scaldaferri M, Audisio E, Boscaro E, et al
    Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.
    Leuk Lymphoma. 2024 Nov 8:1-2. doi: 10.1080/10428194.2024.2427266.
    PubMed    


  164. KORSHOLM C, Bulow C, Christensen M, Dalhoff K, et al
    Drug exposure and measurable residual disease in chronic lymphocytic leukemia: a systematic review.
    Leuk Lymphoma. 2024 Nov 7:1-11. doi: 10.1080/10428194.2024.2412289.
    PubMed     Abstract available


  165. LECORNEC N, Duchmann M, Itzykson R
    Single-cell sequencing applications in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Nov 4:1-15. doi: 10.1080/10428194.2024.2422833.
    PubMed     Abstract available


  166. TAM C, Zhao FL, Azam S, Li SC, et al
    Real-world treatment patterns and outcomes for patients with CLL using the Australian pharmaceutical benefits scheme (PBS) dataset.
    Leuk Lymphoma. 2024;65:1576-1585.
    PubMed     Abstract available


    October 2024
  167. THARAKAN S, Tremblay D, Azzi J
    Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.
    Leuk Lymphoma. 2024 Oct 25:1-14. doi: 10.1080/10428194.2024.2414112.
    PubMed     Abstract available


  168. ROTTER LK, Alhajahjeh A, Stempel JM, Grimshaw AA, et al
    Analyzing determinants of premature trial discontinuation in leukemia clinical trials.
    Leuk Lymphoma. 2024 Oct 23:1-9. doi: 10.1080/10428194.2024.2416565.
    PubMed     Abstract available


  169. KIM SA, Jung M, Kim H, Byun JM, et al
    MG4101, an allogeneic natural killer cell, in patients with relapsed or refractory acute myeloid leukemia: a pilot study.
    Leuk Lymphoma. 2024 Oct 22:1-8. doi: 10.1080/10428194.2024.2414903.
    PubMed     Abstract available


  170. DEHGHANI SS, Wang Y, Ramesh KH, Cooper D, et al
    Atypical chronic myeloid leukemia (CML) with ETV6-ABL1 mutation managed successfully with a third-generation TKI and hematopoietic stem cell transplant.
    Leuk Lymphoma. 2024 Oct 18:1-3. doi: 10.1080/10428194.2024.2403666.
    PubMed    


  171. RIBERA JM, Torrent A
    Novel prognostic factors and therapeutic advances in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Oct 18:1-11. doi: 10.1080/10428194.2024.2416569.
    PubMed     Abstract available


  172. KANKARIA RA, Jones JB, Zargari M, Alexander DW, et al
    Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax.
    Leuk Lymphoma. 2024 Oct 16:1-4. doi: 10.1080/10428194.2024.2416573.
    PubMed    


  173. MOHAMMAD EM, El-Ayadi M, Kamel A, Ebeid E, et al
    Early impact of treatment modifications adopted for acute lymphoblastic leukemia during SARS-CoV-2 pandemic; a single center experience and lessons for LMICs.
    Leuk Lymphoma. 2024 Oct 9:1-7. doi: 10.1080/10428194.2024.2411432.
    PubMed     Abstract available


  174. SHANG Q, Wang Y, Lu A, Jia Y, et al
    Impact of pre-infusion disease burden on outcomes in pediatric relapsed/refractory B-cell lymphoblastic leukemia following anti-CD19 CAR T-cell therapy.
    Leuk Lymphoma. 2024 Oct 8:1-10. doi: 10.1080/10428194.2024.2406958.
    PubMed     Abstract available


  175. BRUNER SA, DiPippo AJ, Rausch CR
    Dose-adjusted direct oral anticoagulants (DOACs) in patients with acute leukemia: experience of a tertiary cancer care center.
    Leuk Lymphoma. 2024 Oct 7:1-3. doi: 10.1080/10428194.2024.2411626.
    PubMed    


  176. SHADMAN M, Salkar M, Srivastava B, Karve S, et al
    Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Oct 1:1-10. doi: 10.1080/10428194.2024.2402814.
    PubMed     Abstract available


    September 2024
  177. ZABLONSKI KG, Skupa SA, Eiken AP, Sundaram S, et al
    Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 27:1-9. doi: 10.1080/10428194.2024.2398663.
    PubMed     Abstract available


  178. SHANGGUAN X, Huang Y, Chen C, Wu W, et al
    Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 23:1-12. doi: 10.1080/10428194.2024.2404957.
    PubMed     Abstract available


  179. KOPMAR NE, Qu X, Liu Y, Gooley TA, et al
    Prognostic significance of chromosomal genomic array testing in adults with newly-diagnosed acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 19:1-4. doi: 10.1080/10428194.2024.2404959.
    PubMed    


  180. DE SA H, Deloughery T, Kaempf A, Lachowiez C, et al
    Thromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Sep 18:1-10. doi: 10.1080/10428194.2024.2405874.
    PubMed     Abstract available


  181. OMRAN MM, Ibrahim AB, Abdelfattah R, Moussa HS, et al
    The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib.
    Leuk Lymphoma. 2024 Sep 18:1-8. doi: 10.1080/10428194.2024.2403671.
    PubMed     Abstract available


  182. CHEN EC, Flamand Y, Tiao E, DeAngelo DJ, et al
    Incidence, duration, and severity of neutropenia in adults with B-cell acute lymphoblastic leukemia receiving blinatumomab consolidation.
    Leuk Lymphoma. 2024 Sep 16:1-8. doi: 10.1080/10428194.2024.2402808.
    PubMed     Abstract available


  183. YIN Z, Gao Y, Bu X, Wang J, et al
    Homoharringtonine sensitized resistant acute myeloid leukemia cells to venetoclax-induced apoptosis.
    Leuk Lymphoma. 2024 Sep 5:1-13. doi: 10.1080/10428194.2024.2400228.
    PubMed     Abstract available


  184. HUNTER S, Ryland G, Pang JM, Ninkovic S, et al
    Chronic lymphocytic leukemia with MDM2 amplification as an alternative pathway to TP53 dysfunction.
    Leuk Lymphoma. 2024 Sep 4:1-4. doi: 10.1080/10428194.2024.2398659.
    PubMed    


  185. GIL KB, Abbott D, Amaya ML, Schwartz M, et al
    Response to intensive induction chemotherapy after failure of frontline azacitidine and venetoclax in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Sep 4:1-3. doi: 10.1080/10428194.2024.2397570.
    PubMed    


  186. DEODATO M, Frustaci AM, Zappaterra A, Rapella A, et al
    Advances in the understanding of molecular genetics and therapy of Richter transformation in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Sep 2:1-12. doi: 10.1080/10428194.2024.2398660.
    PubMed     Abstract available


  187. HAYASHI H, Morikawa Y, Akahoshi S, Ikegawa K, et al
    Octreotide as prophylaxis against asparaginase-associated pancreatitis: a case series study.
    Leuk Lymphoma. 2024;65:1366-1369.
    PubMed    


  188. RAVANDI F, Subklewe M, Walter RB, Vachhani P, et al
    Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
    Leuk Lymphoma. 2024;65:1281-1291.
    PubMed     Abstract available


  189. ABUASAB T, Mohamed S, Pemmaraju N, Kadia TM, et al
    BRAF mutation in myeloid neoplasm: incidences and clinical outcomes.
    Leuk Lymphoma. 2024;65:1344-1349.
    PubMed     Abstract available


  190. SABILE JMG, Swords R, Tyner JW
    Evaluating targeted therapies in older patients with TP53-mutated AML.
    Leuk Lymphoma. 2024;65:1201-1218.
    PubMed     Abstract available


  191. KOBAYASHI Y, Ando K, Imaizumi Y, Sakamoto H, et al
    RUNX1 expression is regulated by a super-enhancer and is a therapeutic target in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2024 Sep 1:1-13. doi: 10.1080/10428194.2024.2393258.
    PubMed     Abstract available


    August 2024
  192. SCHWARTZ MS, Muffly LS
    Predicting relapse in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 31:1-7. doi: 10.1080/10428194.2024.2387728.
    PubMed     Abstract available


  193. OSTERGAARD A, Boer JM, van Leeuwen FN, Pieters R, et al
    IKZF1 in acute lymphoblastic leukemia: the rise before the fall?
    Leuk Lymphoma. 2024 Aug 29:1-11. doi: 10.1080/10428194.2024.2396046.
    PubMed     Abstract available


  194. NGO D, Tinajero J, Song JY, Ma H, et al
    The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2024 Aug 18:1-9. doi: 10.1080/10428194.2024.2392823.
    PubMed     Abstract available


  195. PRASERTSAN P, McNeil EB, Songthawee N, Chavananon S, et al
    Risk factors and development of a predictive score model for tumor lysis syndrome in childhood leukemia: a 10-year experience from a single tertiary hospital in Thailand.
    Leuk Lymphoma. 2024 Aug 18:1-7. doi: 10.1080/10428194.2024.2390582.
    PubMed     Abstract available


  196. JEANSELME P, Tavitian S, Lapierre L, Vergez F, et al
    Long-term exposure and response to azacitidine for post-hematopoietic stem cell transplantation relapse of early T-cell precursor acute lymphoblastic leukemia: a case report and review of the literature.
    Leuk Lymphoma. 2024 Aug 14:1-6. doi: 10.1080/10428194.2024.2390572.
    PubMed     Abstract available


  197. CELLINI A, Salvalaggio A, Velasco R, Arnan M, et al
    Arsenic trioxide-induced peripheral neuropathy: prospective clinical and neurophysiological evaluation in a cohort of patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2024 Aug 13:1-4. doi: 10.1080/10428194.2024.2391899.
    PubMed    


  198. PELLAND AA, Deschenes-Simard X, Savard X, Giguere P, et al
    Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study.
    Leuk Lymphoma. 2024 Aug 11:1-9. doi: 10.1080/10428194.2024.2390574.
    PubMed     Abstract available


  199. HU D, Shen K, Guo Y, Bao XB, et al
    The clinical implications of BCOR mutations in a large cohort of acute myeloid leukemia patients: a 5-year single-center retrospective study.
    Leuk Lymphoma. 2024 Aug 10:1-10. doi: 10.1080/10428194.2024.2387730.
    PubMed     Abstract available


  200. LIN L, Xue S, Chen J, Gu C, et al
    Olaparib combined with low-dose chemotherapy for relapsed AML1::ETO positive acute myeloid leukemia in elderly patient.
    Leuk Lymphoma. 2024;65:1181-1185.
    PubMed    


  201. VERVOORDELDONK MYL, Hengeveld PJ, Levin MD, Langerak AW, et al
    B cell receptor signaling proteins as biomarkers for progression of CLL requiring first-line therapy.
    Leuk Lymphoma. 2024;65:1031-1043.
    PubMed     Abstract available


  202. MAEKAWA F, Hayashida M, Takeoka K, Fukutsuka K, et al
    Two recurrent types of IGH::5' BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the VDJ and class switch recombination processes, respectively.
    Leuk Lymphoma. 2024;65:1100-1109.
    PubMed     Abstract available


  203. CHARALAMPOUS C, Doucette K, Chappell A, Vesole DH, et al
    Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
    Leuk Lymphoma. 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
    PubMed    


    July 2024
  204. DALAL P, Dalal J
    PTCy-ATG mutually exclusive or additive? Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 31:1-2. doi: 10.1080/10428194.2024.2379976.
    PubMed    


  205. CHOI YJ, Kook HW, Lee ST, Song J, et al
    The utility of next generation sequencing-based minimal residual disease monitoring in a post-myeloproliferative neoplasm acute myeloid leukemia patient: a case report.
    Leuk Lymphoma. 2024 Jul 29:1-4. doi: 10.1080/10428194.2024.2385498.
    PubMed    


  206. JAIN U, Rahim F, Jain B, Tresa Mathew A, et al
    Trends in location of death for individuals with acute myeloid leukemia in the United States.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382330.
    PubMed    


  207. ZHANG B, Mahsoub S, Weinberg O, Germans SK, et al
    Clinicopathologic characteristics of de novo NF1-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 27:1-4. doi: 10.1080/10428194.2024.2382329.
    PubMed    


  208. SRIPORNSAWAN P, Chavananon S, Kittivisuit S, Songthawee N, et al
    Long-term survival outcome of childhood acute myeloid leukemia: a 43-year experience in Thailand, a resource-limited country.
    Leuk Lymphoma. 2024 Jul 26:1-10. doi: 10.1080/10428194.2024.2382916.
    PubMed     Abstract available


  209. TOHO M, Yasunaga M, Masuda Y, Shimura A, et al
    Adult T-cell leukemia-lymphoma with neurolymphomatosis successfully controlled by valemetostat: a case report and review of literature.
    Leuk Lymphoma. 2024 Jul 25:1-5. doi: 10.1080/10428194.2024.2381646.
    PubMed    


  210. FANG J, Shankar N, Bao L, Haag M, et al
    Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.
    Leuk Lymphoma. 2024 Jul 25:1-10. doi: 10.1080/10428194.2024.2382923.
    PubMed     Abstract available


  211. TARANTINI F, Cumbo C, Anelli L, Zagaria A, et al
    Venetoclax-based treatment in acute myeloid leukemia: an unexpected bonus on the path to allogeneic hematopoietic stem cell transplant?
    Leuk Lymphoma. 2024 Jul 23:1-12. doi: 10.1080/10428194.2024.2381649.
    PubMed     Abstract available


  212. MORENO-LORENZANA D, Juarez-Velazquez R, Reyes-Leon A, Martinez-Anaya D, et al
    CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia.
    Leuk Lymphoma. 2024 Jul 21:1-11. doi: 10.1080/10428194.2024.2378817.
    PubMed     Abstract available


  213. TRAN QUANG V, Wagner-Ballon O, Sloma I
    Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
    PubMed     Abstract available


  214. BORSOI L, Costa F, Milano C, Segantin G, et al
    Elicitation of societal preferences for chronic lymphocytic leukemia's treatments: a discrete choice experiment.
    Leuk Lymphoma. 2024 Jul 9:1-11. doi: 10.1080/10428194.2024.2374041.
    PubMed     Abstract available


  215. HU M, Li J, Hu T, Zhang Z, et al
    Anti-thymocyte globulin combined with post-transplantation cyclophosphamide reduce graft-versus-host disease in hematopoietic stem cell transplantation for pediatric leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-10. doi: 10.1080/10428194.2024.2376179.
    PubMed     Abstract available


  216. DIEBOLD K, Bourne G, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jul 7:1-3. doi: 10.1080/10428194.2024.2373324.
    PubMed    


  217. TORELI ACM, Miranda-Galvis M, Sharara M, Addas-Carvalho M, et al
    Exploring SARS-CoV-2 infection and vaccine-induced immunity in chronic myeloid leukemia patients: insights from real-world data in Brazil and the United States.
    Leuk Lymphoma. 2024 Jul 5:1-10. doi: 10.1080/10428194.2024.2367057.
    PubMed     Abstract available


  218. LAVIE G, Tadmor T
    It's time to change the standard of care for hairy cell leukemia?!
    Leuk Lymphoma. 2024 Jul 5:1-3. doi: 10.1080/10428194.2024.2371497.
    PubMed    


  219. ALHAJAHJEH A, Bewersdorf JP, Bystrom RP, Zeidan AM, et al
    Acute myeloid leukemia (AML) with chromosome 3 inversion: biology, management, and clinical outcome.
    Leuk Lymphoma. 2024 Jul 4:1-11. doi: 10.1080/10428194.2024.2367040.
    PubMed     Abstract available


  220. TAKIZAWA J, Teshima T, Ennishi D, Ichikawa S, et al
    Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
    Leuk Lymphoma. 2024 Jul 1:1-9. doi: 10.1080/10428194.2024.2370436.
    PubMed     Abstract available


  221. SURESH D, Rastogi P, Bal A, Lad D, et al
    Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles.
    Leuk Lymphoma. 2024 Jul 1:1-16. doi: 10.1080/10428194.2024.2372408.
    PubMed     Abstract available


  222. GOERGEN E, Al-Sawaf O
    The prognostic significance of genomic complexity in patients with CLL.
    Leuk Lymphoma. 2024;65:873-881.
    PubMed     Abstract available


    June 2024
  223. ANDERSON LJ, Girguis M, Kim E, Shewale J, et al
    A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden.
    Leuk Lymphoma. 2024 Jun 27:1-10. doi: 10.1080/10428194.2024.2360536.
    PubMed     Abstract available


  224. YU G, Zhang W, Basyal M, Nishida Y, et al
    The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases.
    Leuk Lymphoma. 2024 Jun 13:1-16. doi: 10.1080/10428194.2024.2364839.
    PubMed     Abstract available


  225. ABE C, Keto J, Lilja M, Konradsen M, et al
    Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data.
    Leuk Lymphoma. 2024 Jun 11:1-9. doi: 10.1080/10428194.2024.2363430.
    PubMed     Abstract available


  226. BHATLA T, Cooper S, Hogan LE
    Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what's next?
    Leuk Lymphoma. 2024 Jun 11:1-7. doi: 10.1080/10428194.2024.2362408.
    PubMed     Abstract available


  227. CHANG JE, Wang T, Kim K, Folstad M, et al
    Maintenance low-dose fixed duration lenalidomide and rituximab following bendamustine and rituximab induction in previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jun 10:1-9. doi: 10.1080/10428194.2024.2360535.
    PubMed     Abstract available


  228. SHORT NJ, Kantarjian H, Jabbour E
    Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
    Leuk Lymphoma. 2024 Jun 8:1-13. doi: 10.1080/10428194.2024.2364043.
    PubMed     Abstract available


  229. GERA K, Cline C, Al-Mansour Z, Medvec A, et al
    A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Jun 6:1-9. doi: 10.1080/10428194.2024.2361111.
    PubMed     Abstract available


  230. SHOUSE G, Chen L, Siddiqi T, Muir A, et al
    A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
    Leuk Lymphoma. 2024 Jun 5:1-4. doi: 10.1080/10428194.2024.2361841.
    PubMed    


  231. FREI CR, Ryan K, Obodozie-Ofoegbu GO, Moore AM, et al
    Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jun 4:1-4. doi: 10.1080/10428194.2024.2360526.
    PubMed    


  232. FANG J, Bosma G, Aisner D, McMahon C, et al
    White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2024;65:800-807.
    PubMed     Abstract available


    May 2024
  233. MINNEMA MC, Yin X, Davi R, Keeping S, et al
    Outcomes of patients aged >/=26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
    Leuk Lymphoma. 2024 May 24:1-10. doi: 10.1080/10428194.2024.2353877.
    PubMed     Abstract available


  234. BELDZINSKA-GADEK K, Zarzycka E, Pastuszak K, Borman K, et al
    Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
    Leuk Lymphoma. 2024 May 22:1-11. doi: 10.1080/10428194.2024.2351194.
    PubMed     Abstract available


  235. ZHENG Y, Li J, Wen H, Weng K, et al
    Experience in improving treatment outcomes for childhood acute lymphoblastic leukemia: real-world results for a province in China, 2011-2020.
    Leuk Lymphoma. 2024 May 20:1-11. doi: 10.1080/10428194.2024.2350665.
    PubMed     Abstract available


  236. MARVIN-PEEK J, Jen WY, Kantarjian HM, McCue D, et al
    Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
    Leuk Lymphoma. 2024 May 15:1-10. doi: 10.1080/10428194.2024.2349700.
    PubMed     Abstract available


  237. DESPAS F, Chaouki M, de Barros S, Bonneau B, et al
    Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
    Leuk Lymphoma. 2024 May 15:1-3. doi: 10.1080/10428194.2024.2353330.
    PubMed    


  238. WANG CP, Ferreira JE, Placek A, Aguayo-Hiraldo P, et al
    A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome.
    Leuk Lymphoma. 2024 May 11:1-5. doi: 10.1080/10428194.2024.2347577.
    PubMed     Abstract available


  239. HUNTINGTON SF, Cheng WY, Sarpong EM, Leng S, et al
    Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study.
    Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
    PubMed     Abstract available


  240. ROGERS KA, Thompson PA
    Pairing obinutuzumab with venetoclax in relapsed CLL.
    Leuk Lymphoma. 2024;65:543-545.
    PubMed    


  241. GARCIAZ S, Berton G, Hospital MA, Guille A, et al
    Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
    Leuk Lymphoma. 2024;65:700-703.
    PubMed    


  242. OKABE S, Moriyama M, Gotoh A
    Effects of bortezomib on ponatinib-resistant Philadelphia chromosome-positive cells.
    Leuk Lymphoma. 2024;65:696-699.
    PubMed    


  243. FATIMA N, Shen Y, Crassini K, Burling O, et al
    The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells in vitro.
    Leuk Lymphoma. 2024;65:585-597.
    PubMed     Abstract available


    April 2024
  244. NESR G, Claudiani S, Milojkovic D, Innes A, et al
    Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-6. doi: 10.1080/10428194.2024.2343758.
    PubMed     Abstract available


  245. STEMPEL JM, Shallis RM, Wong R, Podoltsev NA, et al
    Challenges in management of older patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 23:1-14. doi: 10.1080/10428194.2024.2342559.
    PubMed     Abstract available


  246. BEWERSDORF JP, Patel KK, Shallis RM, Podoltsev NA, et al
    Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-9. doi: 10.1080/10428194.2024.2344052.
    PubMed     Abstract available


  247. FLECK C, Karabinos A, Cook A, Moore DC, et al
    Evaluation of safety outcomes with transitioning obinutuzumab from standard rate to short duration infusion in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2024 Apr 22:1-2. doi: 10.1080/10428194.2024.2341999.
    PubMed    


  248. TINAJERO J, Ngo D, Zhang J, Tsai NC, et al
    High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.
    Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506.
    PubMed    


  249. STEIN EM, Fathi AT, Harb WA, Colak G, et al
    Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignancies.
    Leuk Lymphoma. 2024;65:503-510.
    PubMed     Abstract available


  250. PARVIZ M, Agius R, Rotbain EC, Vainer N, et al
    Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning.
    Leuk Lymphoma. 2024;65:449-459.
    PubMed     Abstract available


  251. ALDOSS I, Clark MC, Wang X, Forman SJ, et al
    Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?
    Leuk Lymphoma. 2024;65:440-448.
    PubMed     Abstract available


    March 2024
  252. CORTES J, Jonas BA, Schiller G, Mims A, et al
    Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
    Leuk Lymphoma. 2024 Mar 27:1-8. doi: 10.1080/10428194.2024.2333451.
    PubMed     Abstract available


  253. MATTHEWS A, Fenu E, Skuli SJ, Harris JC, et al
    Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach.
    Leuk Lymphoma. 2024 Mar 27:1-4. doi: 10.1080/10428194.2024.2332505.
    PubMed    


  254. ABDALLAH AM, Hafez H, Madney Y, Ahmed S, et al
    Predictive value of early molecular response to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 21:1-4. doi: 10.1080/10428194.2024.2331625.
    PubMed    


  255. LACZKO D, Poveda-Rogers C, Matthews AH, Snaith O, et al
    RAD21 mutations in acute myeloid leukemia.
    Leuk Lymphoma. 2024 Mar 20:1-7. doi: 10.1080/10428194.2024.2328233.
    PubMed     Abstract available


  256. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    PubMed     Abstract available


    February 2024
  257. NASKAR S, Paul T, Kulkarni JD, Anand KC, et al
    TCF3::PBX1 fusion pediatric B acute lymphoblastic leukemia in disguise behind the eyes - an unusual clinicopathologic presentation with hyperdiploid clone.
    Leuk Lymphoma. 2024 Feb 26:1-5. doi: 10.1080/10428194.2024.2320827.
    PubMed    


  258. HOFER KD, Buhler MM, Roncador M, Rechsteiner M, et al
    Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey.
    Leuk Lymphoma. 2024 Feb 22:1-8. doi: 10.1080/10428194.2024.2315171.
    PubMed     Abstract available


  259. MURPHY L, Siegele B, Carstens B, Hartman L, et al
    A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy.
    Leuk Lymphoma. 2024 Feb 19:1-5. doi: 10.1080/10428194.2024.2315159.
    PubMed    


  260. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    PubMed     Abstract available


  261. YARED JA, Lee TY, Cooke CE, Johnson A, et al
    Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
    Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
    PubMed     Abstract available


  262. EL-ASHWAH S, Salmanton-Garcia J, Bilgin YM, Itri F, et al
    The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey.
    Leuk Lymphoma. 2024;65:199-208.
    PubMed     Abstract available


  263. JOHNSON SM, Haberberger J, Galeotti J, Ramkissoon L, et al
    Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
    Leuk Lymphoma. 2024;65:209-218.
    PubMed     Abstract available


    January 2024
  264. LEI MM, Sorial MN, Lou U, Yu M, et al
    Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Leuk Lymphoma. 2024 Jan 31:1-7. doi: 10.1080/10428194.2024.2310144.
    PubMed     Abstract available


  265. NASR AA, Fund X, Barreau S, Desterke C, et al
    BIRC-3 mutated monoclonal B lymphocytosis without evolution to chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2024 Jan 31:1-4. doi: 10.1080/10428194.2024.2308665.
    PubMed    


  266. TADMOR T, Levy Yurkovski I
    Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.
    Leuk Lymphoma. 2024 Jan 22:1-4. doi: 10.1080/10428194.2024.2304026.
    PubMed    


  267. FU S, Alhaj Z, Huynh D
    Prevalence of primary chronic lymphocytic leukemia in the United States: a cross-sectional study using the SEER database.
    Leuk Lymphoma. 2024 Jan 22:1-2. doi: 10.1080/10428194.2023.2300714.
    PubMed    


  268. BANERJI V, Aw A, Laferriere N, Abdel-Samad N, et al
    Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice.
    Leuk Lymphoma. 2024 Jan 18:1-9. doi: 10.1080/10428194.2024.2301738.
    PubMed     Abstract available


  269. NGO D, Tinajero J, Li S, Palmer J, et al
    Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
    Leuk Lymphoma. 2024 Jan 2:1-6. doi: 10.1080/10428194.2023.2292473.
    PubMed     Abstract available


    December 2023
  270. SALTER B, Radford JM, Berg T, Leber B, et al
    The successful management of acute promyelocytic leukemia during pregnancy: a case report.
    Leuk Lymphoma. 2023 Dec 19:1-4. doi: 10.1080/10428194.2023.2295786.
    PubMed    


  271. MUTTI M, Cordella S, Parisotto A, Bettelli F, et al
    Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature.
    Leuk Lymphoma. 2023 Dec 19:1-5. doi: 10.1080/10428194.2023.2294695.
    PubMed    


  272. WANG L, Gao L, Liang Z, Cen X, et al
    Efficacy and safety of coadministration of venetoclax and anti-fungal agents under therapeutic drug monitor in unfit acute myeloid leukemia and high-risk myelodysplastic syndrome with neutropenia: a single-center retrospective study.
    Leuk Lymphoma. 2023 Dec 9:1-10. doi: 10.1080/10428194.2023.2290465.
    PubMed     Abstract available


  273. JEN WY, Sasaki K, Rausch CR, DiNardo CD, et al
    Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
    Leuk Lymphoma. 2023 Dec 6:1-5. doi: 10.1080/10428194.2023.2290467.
    PubMed     Abstract available


  274. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
    Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
    Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
    PubMed    


  275. MURTON A, Forsyth C, Ross DM, Grigg A, et al
    Significant heterogeneity in management of calreticulin-mutated essential thrombocythemia and its progression to myelofibrosis: results of a national survey.
    Leuk Lymphoma. 2023;64:2018-2025.
    PubMed     Abstract available


  276. STEIN EM, de Botton S, Cluzeau T, Pigneux A, et al
    Use of tamibarotene, a potent and selective RARalpha agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.
    Leuk Lymphoma. 2023;64:1992-2001.
    PubMed     Abstract available


  277. REDD RA, Ford J, Lei M, Abramson JS, et al
    Combined analysis of the impact of second-generation BTK inhibitors on patient outcomes.
    Leuk Lymphoma. 2023;64:2296-2305.
    PubMed     Abstract available


  278. YANG T, Mahmood N, Goldberg B, Cevallos J, et al
    Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias.
    Leuk Lymphoma. 2023;64:2338-2342.
    PubMed    


  279. TOMASULO E, Paul S, Mu R, Tian X, et al
    Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.
    Leuk Lymphoma. 2023;64:2306-2315.
    PubMed     Abstract available


  280. SMITH AL, Pal D, Martinez-Rico R, Eiken AP, et al
    Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies.
    Leuk Lymphoma. 2023;64:2333-2337.
    PubMed    


  281. ZHANG X, Wang T, Zhang Y, Wang F, et al
    Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
    Leuk Lymphoma. 2023;64:2133-2139.
    PubMed     Abstract available


    November 2023
  282. LAI X, Xiao J, Wang T, Hou C, et al
    Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
    Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
    PubMed     Abstract available


  283. OU J, Xu X, Deng S, Liang H, et al
    Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen.
    Leuk Lymphoma. 2023 Nov 8:1-9. doi: 10.1080/10428194.2023.2278026.
    PubMed     Abstract available


  284. FATIMA N, Best OG, Belov L, Christopherson RI, et al
    The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cells.
    Leuk Lymphoma. 2023 Nov 7:1-8. doi: 10.1080/10428194.2023.2275530.
    PubMed     Abstract available


  285. KHOUDERCHAH CJ, Benitez LL, Marini BL, Fraga M, et al
    Tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax and hypomethylating agents with or without dose ramp-up.
    Leuk Lymphoma. 2023 Nov 6:1-7. doi: 10.1080/10428194.2023.2276056.
    PubMed     Abstract available


  286. SASTOW D, Tatarian J, Salib C, Lin TL, et al
    Response to 'blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives'.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2274658.
    PubMed    


  287. FRATER JL
    Blast identification in cerebrospinal fluid specimens from patients with acute myeloid leukemia: laboratory perspectives.
    Leuk Lymphoma. 2023 Nov 3:1-2. doi: 10.1080/10428194.2023.2273749.
    PubMed    


  288. SOSNIA O, Pruszczyk K, Danecki M, Wasik-Szczepanek E, et al
    Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
    Leuk Lymphoma. 2023 Nov 3:1-12. doi: 10.1080/10428194.2023.2277140.
    PubMed     Abstract available


  289. TRINQUAND A, Betts DR, Harte S, Sills A, et al
    Adapted risk stratification and intensive chemotherapy abrogate the poor prognosis of pediatric B acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21): a National cohort analysis.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276061.
    PubMed    


  290. RAMACHANDRA N, Gupta M, Schwartz L, Todorova T, et al
    Role of IL8 in myeloid malignancies.
    Leuk Lymphoma. 2023;64:1742-1751.
    PubMed     Abstract available


  291. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    PubMed    


    October 2023
  292. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
    MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
    Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
    PubMed     Abstract available


  293. CONTRERAS YAMETTI GP, Robbins G, Chowdhury A, Narang S, et al
    SETD2 mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 24:1-13. doi: 10.1080/10428194.2023.2273752.
    PubMed     Abstract available


  294. HUNTINGTON SF, de Nigris E, Puckett J, Kamal-Bahl S, et al
    Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Oct 23:1-10. doi: 10.1080/10428194.2023.2256911.
    PubMed     Abstract available


  295. LIAO C, Nie J, Xu XJ, Zhang JY, et al
    The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2023 Oct 11:1-9. doi: 10.1080/10428194.2023.2266075.
    PubMed     Abstract available


  296. ZAHID MF, Kainthla R
    Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene.
    Leuk Lymphoma. 2023 Oct 9:1-5. doi: 10.1080/10428194.2023.2264428.
    PubMed    


  297. GAUT D, Oliai C, Boiarsky J, Zhang S, et al
    Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
    Leuk Lymphoma. 2023 Oct 6:1-9. doi: 10.1080/10428194.2023.2264426.
    PubMed     Abstract available


  298. YASU T, Gando Y, Shirota M, Kosugi N, et al
    Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
    Leuk Lymphoma. 2023 Oct 5:1-4. doi: 10.1080/10428194.2023.2264427.
    PubMed    


  299. SABILE JMG, Kaempf A, Tomic K, Manu GP, et al
    A retrospective validation of the IPSS-M molecular score in primary and therapy-related myelodysplastic syndromes (MDS).
    Leuk Lymphoma. 2023;64:1689-1694.
    PubMed     Abstract available


  300. CHAI J, Choudhuri J, Wang Q, Fang Y, et al
    Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Leuk Lymphoma. 2023;64:1662-1672.
    PubMed     Abstract available


    September 2023
  301. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    PubMed     Abstract available


  302. HUNTINGTON SF, Manzoor BS, Puckett JT, Kamal-Bahl S, et al
    Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-8. doi: 10.1080/10428194.2023.2255326.
    PubMed     Abstract available


  303. LESEGRETAIN A, Brunner A, Benzohra A, Fathi AT, et al
    Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
    Leuk Lymphoma. 2023 Sep 15:1-9. doi: 10.1080/10428194.2023.2252123.
    PubMed     Abstract available


  304. IELO C, Scalzulli E, Carmosino I, Pepe S, et al
    Validation of imatinib therapy failure score (IMTF) in chronic phase chronic myeloid leukemia in real life practice.
    Leuk Lymphoma. 2023 Sep 10:1-3. doi: 10.1080/10428194.2023.2255804.
    PubMed     Abstract available


  305. LA J, Lee MH, Brophy MT, Do NV, et al
    Baseline correlates of frailty and its association with survival in United States veterans with acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 6:1-10. doi: 10.1080/10428194.2023.2254434.
    PubMed     Abstract available


  306. BHATNAGAR B, Zhao Q, Mims AS, Vasu S, et al
    Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
    Leuk Lymphoma. 2023 Sep 4:1-10. doi: 10.1080/10428194.2023.2253480.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum